October 13, 2020
1 min watch
Sandborn WJ, et al. Abstract OP089. Presented at: UEG Week Virtual. Oct. 11-13, 2020.
The study was supported by Janssen Research & Development.
In this exclusive video, William J. Sandborn, MD, from the University of California, San Diego, discusses interim results from the phase 2 GALAXI 1 study of Tremfya in patients with Crohn’s disease.
In the study, researchers explored the efficacy and safety of three different doses of the drug (guselkumab, Janssen) against placebo, as well as a reference comparator, Stelara (ustekinumab, Janssen).
All three doses induced greater improvements in clinical and endoscopic outcomes compared with placebo, according to Sandborn.